21.73
price down icon0.64%   -0.14
after-market After Hours: 21.77 0.04 +0.18%
loading
Arrivent Biopharma Inc stock is traded at $21.73, with a volume of 106.49K. It is down -0.64% in the last 24 hours and down -19.25% over the past month. ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
See More
Previous Close:
$21.87
Open:
$22.11
24h Volume:
106.49K
Relative Volume:
0.71
Market Cap:
$739.17M
Revenue:
-
Net Income/Loss:
$-81.05M
P/E Ratio:
-8.2838
EPS:
-2.6232
Net Cash Flow:
$-68.97M
1W Performance:
-1.36%
1M Performance:
-19.25%
6M Performance:
-20.37%
1Y Performance:
+10.81%
1-Day Range:
Value
$21.40
$22.16
1-Week Range:
Value
$21.34
$22.92
52-Week Range:
Value
$14.35
$36.37

Arrivent Biopharma Inc Stock (AVBP) Company Profile

Name
Name
Arrivent Biopharma Inc
Name
Phone
240-780-6356
Name
Address
18 CAMPUS BLVD., NEWTOWN SQUARE
Name
Employee
52
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
AVBP's Discussions on Twitter

Compare AVBP with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
AVBP
Arrivent Biopharma Inc
21.73 739.17M 0 -81.05M -68.97M -2.6232
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
500.01 128.40B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
744.83 81.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
571.00 34.69B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
233.07 30.17B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beone Medicines Ltd Adr
242.66 26.02B 3.32B -860.46M -1.04B -8.32

Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-10-25 Initiated Guggenheim Buy
Jul-22-24 Initiated Oppenheimer Outperform
Apr-30-24 Initiated H.C. Wainwright Buy
Feb-20-24 Initiated Citigroup Buy
Feb-20-24 Initiated Goldman Buy
Feb-20-24 Initiated Jefferies Buy
View All

Arrivent Biopharma Inc Stock (AVBP) Latest News

pulisher
01:43 AM

ArriVent BioPharma (NASDAQ:AVBP) Now Covered by Analysts at Guggenheim - Defense World

01:43 AM
pulisher
Mar 10, 2025

Guggenheim starts ArriVent Biopharma with a Buy on firmonertinib potential - TipRanks

Mar 10, 2025
pulisher
Mar 09, 2025

ArriVent BioPharma (NASDAQ:AVBP) Earns “Buy” Rating from HC Wainwright - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

Here's What Could Help ArriVent BioPharma, Inc. (AVBP) Maintain Its Recent Price Strength - MSN

Mar 08, 2025
pulisher
Mar 08, 2025

H.C. Wainwright maintains Buy on ArriVent shares, $39 target By Investing.com - Investing.com Canada

Mar 08, 2025
pulisher
Mar 08, 2025

ArriVent BioPharma Reports 2024 Financial Results and Key Achievements - MSN

Mar 08, 2025
pulisher
Mar 07, 2025

H.C. Wainwright maintains Buy on ArriVent shares, $39 target - Investing.com India

Mar 07, 2025
pulisher
Mar 07, 2025

Rhumbline Advisers Purchases 3,069 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

FY2025 EPS Estimates for AVBP Reduced by Lifesci Capital - Defense World

Mar 07, 2025
pulisher
Mar 06, 2025

New York State Common Retirement Fund Boosts Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World

Mar 06, 2025
pulisher
Mar 04, 2025

ArriVent BioPharma Reports 2024 Financial Results and Progress - MSN

Mar 04, 2025
pulisher
Mar 04, 2025

(AVBP) Investment Report - Stock Traders Daily

Mar 04, 2025
pulisher
Mar 04, 2025

Lepu Biopharma Co., Ltd. Announces Update on New Drug Application of MRG003 -March 03, 2025 - Marketscreener.com

Mar 04, 2025
pulisher
Mar 03, 2025

ArriVent BioPharma, Inc. SEC 10-K Report - TradingView

Mar 03, 2025
pulisher
Mar 03, 2025

ArriVent BioPharma Reports Full Year 2024 Financial Results - The Manila Times

Mar 03, 2025
pulisher
Feb 24, 2025

IPOs Numbers Rise In 2024, But Dwindling Returns Could Diminish Potential In 2025 - Scrip

Feb 24, 2025
pulisher
Feb 22, 2025

Where are the Opportunities in (AVBP) - Stock Traders Daily

Feb 22, 2025
pulisher
Feb 19, 2025

ArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Update - MarketBeat

Feb 19, 2025
pulisher
Feb 16, 2025

Mirae Asset Global Investments Co. Ltd. Makes New Investment in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World

Feb 16, 2025
pulisher
Feb 16, 2025

Mirae Asset Global Investments Co. Ltd. Purchases Shares of 1,123 ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Armenian Reporter

Feb 16, 2025
pulisher
Feb 11, 2025

How To Trade (AVBP) - Stock Traders Daily

Feb 11, 2025
pulisher
Feb 06, 2025

Short Interest in ArriVent BioPharma, Inc. (NASDAQ:AVBP) Expands By 13.1% - MarketBeat

Feb 06, 2025
pulisher
Feb 05, 2025

Deal Watch: Novo Nordisk, IMMvention To Partner On Sickle Cell Disease - News & Insights

Feb 05, 2025
pulisher
Feb 04, 2025

Asia’s NewCo Model, FDA tipping point, Vertex’s pain drug: a BioCentury podcast - BioCentury

Feb 04, 2025
pulisher
Jan 31, 2025

ArriVent BioPharma, Inc. (NASDAQ:AVBP) Shares Bought by JPMorgan Chase & Co. - Defense World

Jan 31, 2025
pulisher
Jan 30, 2025

(AVBP) Trading Signals - Stock Traders Daily

Jan 30, 2025
pulisher
Jan 29, 2025

The NewCo boom signals China’s galloping speed of innovation - BioCentury

Jan 29, 2025
pulisher
Jan 28, 2025

Abbvie seeks molecular glue degraders from Neomorph - BioCentury

Jan 28, 2025
pulisher
Jan 27, 2025

ArriVent in Newtown Square Sees Big Potential in New Cancer Drug - DELCO.Today

Jan 27, 2025
pulisher
Jan 27, 2025

ArriVent BioPharma Secures Global Rights to MRG007 in Strategic Deal with Lepu Biopharma - MSN

Jan 27, 2025
pulisher
Jan 27, 2025

IPO excitement heats up as Metsera targets $1.8B valuation, Aurion joins queue - FirstWord Pharma

Jan 27, 2025
pulisher
Jan 25, 2025

Equities Analysts Set Expectations for AVBP Q1 Earnings - Defense World

Jan 25, 2025
pulisher
Jan 24, 2025

HC Wainwright Issues Positive Estimate for AVBP Earnings - MarketBeat

Jan 24, 2025
pulisher
Jan 23, 2025

More China ADCs: Arrivent gets GI cancer drug in $1.2B Lepu deal - BioWorld Online

Jan 23, 2025
pulisher
Jan 23, 2025

ArriVent Biopharma price target raised to $39 from $36 at H.C. Wainwright - Yahoo Finance

Jan 23, 2025
pulisher
Jan 22, 2025

ArriVent Biopharma enters license agreement with Lepu Biopharma - MSN

Jan 22, 2025
pulisher
Jan 22, 2025

Cancer Biotech ArriVent Lands an ADC for GI Malignancies and Makes Best-in-Class Claim - MedCity News

Jan 22, 2025
pulisher
Jan 22, 2025

Intellia makes progress on HAE study; 2 more China drug deals - BioPharma Dive

Jan 22, 2025
pulisher
Jan 22, 2025

ArriVent inks ADC licensing deal with Lepu Biopharma - The Pharma Letter

Jan 22, 2025
pulisher
Jan 22, 2025

ArriVent bets big on experimental cancer drug with potential $1B licensing deal - The Business Journals

Jan 22, 2025
pulisher
Jan 22, 2025

Arrivent Biopharma licenses ex-China rights to Lepu’s ADC for gastrointestinal cancers - BioWorld Online

Jan 22, 2025
pulisher
Jan 22, 2025

ArriVent Joins Chinese Licensing Trend With Potential $1.2B+ ADC Deal with Lepu - BioSpace

Jan 22, 2025
pulisher
Jan 22, 2025

ArriVent BioPharma (NASDAQ:AVBP) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat

Jan 22, 2025
pulisher
Jan 22, 2025

ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers - The Manila Times

Jan 22, 2025
pulisher
Jan 21, 2025

Lepu Biopharma has granted ArriVent Exclusive License for MRG007, a Potential Best-in-Class ADC for the - Digital More

Jan 21, 2025
pulisher
Jan 21, 2025

Lepu Biopharma has granted ArriVent Exclusive License for MRG007, a Potential Best-in-Class ADC for the treatment of Gastrointestinal Cancers - The Manila Times

Jan 21, 2025
pulisher
Jan 21, 2025

Lepu Biopharma Co., Ltd. Enters into an Exclusive Licensing Agreement with Arrivent Biopharma, Inc - Marketscreener.com

Jan 21, 2025
pulisher
Jan 21, 2025

ArriVent BioPharma Enters Exclusive License with Lepu Biopharma - WICZ

Jan 21, 2025
pulisher
Jan 21, 2025

Lepu Biopharma Grants Exclusive License for Novel ADC MRG007 to ArriVent - TipRanks

Jan 21, 2025
pulisher
Jan 21, 2025

ArriVent BioPharma Secures Global Rights to Promising Cancer Drug MRG007 in $1.2B Deal - StockTitan

Jan 21, 2025
pulisher
Jan 20, 2025

(AVBP) Investment Analysis - Stock Traders Daily

Jan 20, 2025

Arrivent Biopharma Inc Stock (AVBP) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$35.96
price up icon 0.98%
$21.98
price down icon 8.97%
$32.75
price down icon 0.79%
$317.87
price up icon 0.62%
$105.35
price down icon 3.15%
biotechnology ONC
$242.66
price down icon 1.78%
Cap:     |  Volume (24h):